BMS-817399

• Description :

  BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis[1].

• UNSPSC :

  12352005

• Target :

  CCR

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ccr1-antagonist-2.html

• Purity :

  99.83

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O[C@@](CCN1C([C@@H](C(C)C)NC(NCC(C)(O)C)=O)=O)(C(C=C2)=CC=C2Cl)C(C)(C1)C

• Molecular Formula :

  C23H36ClN3O4

• Molecular Weight :

  454.00

• References & Citations :

  [1]Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57 (18) :7550-7564.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CCR1

• CAS Number :

  [1202400-18-7]